8 May 2024 - NICE has published evidence-based recommendations on the use of selinexor (Nexpovio) in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma after 4 or more treatments.

Selinexor, in combination with dexamethasone, is recommended for the treatment of adults with multiple myeloma when:

• They have had 4 or more treatments
• The condition is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents and an anti‑CD38 monoclonal antibody (penta-refractory)
• The condition has progressed on the last treatment
• Menarini provides it according to the commercial arrangement.

Read NICE technology appraisal guidance